{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:15:57Z","timestamp":1791375357526,"version":"4.3.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008968","name":"National Research Council Sri Lanka","doi-asserted-by":"publisher","award":["18-030"],"award-info":[{"award-number":["18-030"]}],"id":[{"id":"10.13039\/100008968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hydroxyurea is an antimetabolite drug that induces fetal haemoglobin in sickle cell disease. However, its clinical usefulness in \u03b2-thalassaemia is unproven. We conducted a randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of hydroxyurea in transfusion-dependent \u03b2-thalassaemia. Sixty patients were assigned 1:1 to oral hydroxyurea 10\u201320\u00a0mg\/kg\/day or placebo for 6 months by stratified block randomisation. Hydroxyurea treatment did not alter the blood transfusion volume overall. However, a significantly higher proportion of patients on hydroxyurea showed increases in fetal haemoglobin percentage (89% vs. 59%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05) and reductions in erythropoietic stress as measured by soluble transferrin receptor concentration (79% vs. 40%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Based on fetal haemoglobin induction (&gt;\u20091.5%), 44% of patients were identified as hydroxyurea-responders. Hydroxyurea-responders, required significantly lower blood volume (77\u2009\u00b1\u2009SD27ml\/kg) compared to hydroxyurea-non-responders (108\u2009\u00b1\u2009SD24ml\/kg;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) and placebo-receivers (102\u2009\u00b1\u200928ml\/kg;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Response to hydroxyurea was significantly higher in patients with HbE \u03b2-thalassaemia genotype (50% vs. 0%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) and\n                    <jats:italic>Xmn1<\/jats:italic>\n                    polymorphism of the \u03b3-globin gene (67% vs. 27%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). We conclude that oral hydroxyurea increased fetal haemoglobin percentage and reduced erythropoietic stress of ineffective erythropoiesis in patients with transfusion-dependent \u03b2-thalassaemia. Hydroxyurea reduced the transfusion burden in approximately 40% of patients. Response to hydroxyurea was higher in patients with HbE \u03b2-thalassaemia genotype and\n                    <jats:italic>Xmn<\/jats:italic>\n                    1 polymorphism of the \u03b3-globin gene.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-06774-8","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T06:02:53Z","timestamp":1645077773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent \u03b2-thalassaemia"],"prefix":"10.1038","volume":"12","author":[{"given":"Nirmani","family":"Yasara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nethmi","family":"Wickramarathne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamila","family":"Mettananda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishari","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizri","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumari","family":"Attanayaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rexan","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmani","family":"Wickramasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshman","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aresha","family":"Manamperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Premawardhena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachith","family":"Mettananda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"6774_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","volume":"391","author":"AT Taher","year":"2018","unstructured":"Taher, A. T., Weatherall, D. J. & Cappellini, M. D. Thalassaemia. Lancet 391, 155\u2013167 (2018).","journal-title":"Lancet"},{"key":"6774_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMra2021838","volume":"384","author":"AT Taher","year":"2021","unstructured":"Taher, A. T., Musallam, K. M. & Cappellini, M. D. \u03b2-Thalassemias. N. Engl. J. Med. 384, 727\u2013743 (2021).","journal-title":"N. Engl. J. Med."},{"key":"6774_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.blre.2018.02.001","volume":"32","author":"MD Cappellini","year":"2018","unstructured":"Cappellini, M. D., Porter, J. B., Viprakasit, V. & Taher, A. T. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?. Blood Rev. 32, 300\u2013311 (2018).","journal-title":"Blood Rev."},{"key":"6774_CR4","doi-asserted-by":"publisher","first-page":"e27643","DOI":"10.1002\/pbc.27643","volume":"66","author":"S Mettananda","year":"2019","unstructured":"Mettananda, S. et al. Blood transfusion therapy for beta-thalassemia major and hemoglobin E beta-thalassemia: Adequacy, trends, and determinants in Sri Lanka. Pediatric Blood Cancer 66, e27643 (2019).","journal-title":"Pediatric Blood Cancer"},{"key":"6774_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/bmt.2015.293","volume":"51","author":"D Baronciani","year":"2016","unstructured":"Baronciani, D. et al. Hemopoietic stem cell transplantation in thalassemia: A report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000\u20132010. Bone Marrow Transplant. 51, 536\u2013541 (2016).","journal-title":"Bone Marrow Transplant."},{"key":"6774_CR6","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","volume":"382","author":"MD Cappellini","year":"2020","unstructured":"Cappellini, M. D. et al. A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia. N. Engl. J. Med. 382, 1219\u20131231 (2020).","journal-title":"N. Engl. J. Med."},{"key":"6774_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41467-017-00479-7","volume":"8","author":"S Mettananda","year":"2017","unstructured":"Mettananda, S. et al. Editing an alpha-globin enhancer in primary human hematopoietic stem cells as a treatment for beta-thalassemia. Nat. Commun. 8, 424 (2017).","journal-title":"Nat. Commun."},{"key":"6774_CR8","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","volume":"378","author":"AA Thompson","year":"2018","unstructured":"Thompson, A. A. et al. Gene therapy in patients with transfusion-dependent \u03b2-thalassemia. New Engl. J. Med. 378, 1479\u20131493 (2018).","journal-title":"New Engl. J. Med."},{"key":"6774_CR9","doi-asserted-by":"publisher","first-page":"e0228733","DOI":"10.1371\/journal.pone.0228733","volume":"15","author":"S Mettananda","year":"2020","unstructured":"Mettananda, S. et al. Psychological morbidity among children with transfusion dependent beta-thalassaemia and their parents in Sri Lanka. PLoS ONE 15, e0228733 (2020).","journal-title":"PLoS ONE"},{"key":"6774_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12955-019-1207-9","volume":"17","author":"S Mettananda","year":"2019","unstructured":"Mettananda, S. et al. Health related quality of life among children with transfusion dependent beta-thalassaemia major and haemoglobin E beta-thalassaemia in Sri Lanka: A case control study. Health Qual. Life Outcomes 17, 137 (2019).","journal-title":"Health Qual. Life Outcomes"},{"key":"6774_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13023-021-01757-w","volume":"16","author":"N Yasara","year":"2021","unstructured":"Yasara, N., Premawardhena, A. & Mettananda, S. A comprehensive review of hydroxyurea for beta-haemoglobinopathies: The role revisited during COVID-19 pandemic. Orphanet J. Rare Dis. 16, 114 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"6774_CR12","first-page":"Cd002202","volume":"4","author":"SJ Nevitt","year":"2017","unstructured":"Nevitt, S. J., Jones, A. P. & Howard, J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database System. Rev. 4, Cd002202 (2017).","journal-title":"Cochrane Database System. Rev."},{"key":"6774_CR13","first-page":"CD011579","volume":"10","author":"WC Foong","year":"2016","unstructured":"Foong, W. C., Ho, J. J., Loh, C. K. & Viprakasit, V. Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias. Cochrane Database System. Rev. 10, CD011579 (2016).","journal-title":"Cochrane Database System. Rev."},{"key":"6774_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ajh.21120","volume":"83","author":"A Koren","year":"2008","unstructured":"Koren, A. et al. Response to hydroxyurea therapy in beta-thalassemia. Am. J. Hematol. 83, 366\u2013370 (2008).","journal-title":"Am. J. Hematol."},{"key":"6774_CR15","first-page":"1172","volume":"89","author":"M Yavarian","year":"2004","unstructured":"Yavarian, M., Karimi, M., Bakker, E., Harteveld, C. L. & Giordano, P. C. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica 89, 1172\u20131178 (2004).","journal-title":"Haematologica"},{"key":"6774_CR16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s00277-003-0836-5","volume":"83","author":"M Alebouyeh","year":"2004","unstructured":"Alebouyeh, M., Moussavi, F., Haddad-Deylami, H. & Vossough, P. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening. Ann. Hematol. 83, 430\u2013433 (2004).","journal-title":"Ann. Hematol."},{"key":"6774_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/MPH.0b013e31821b0770","volume":"33","author":"SH Ansari","year":"2011","unstructured":"Ansari, S. H. et al. Efficacy of hydroxyurea in providing transfusion independence in \u03b2-thalassemia. J. Pediatr. Hematol. Oncol. 33, 339\u2013343 (2011).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"6774_CR18","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40618-019-01072-z","volume":"42","author":"M Bordbar","year":"2019","unstructured":"Bordbar, M. et al. Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: A historical cohort study in Southern Iran. J. Endocrinol. Invest. 42, 1467\u20131476 (2019).","journal-title":"J. Endocrinol. Invest."},{"key":"6774_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/08880018.2017.1354948","volume":"34","author":"AH Algiraigri","year":"2017","unstructured":"Algiraigri, A. H., Wright, N. A. M., Paolucci, E. O. & Kassam, A. Hydroxyurea for lifelong transfusion-dependent beta-thalassemia: A meta-analysis. Pediatr. Hematol. Oncol. 34, 435\u2013448 (2017).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"6774_CR20","doi-asserted-by":"crossref","unstructured":"Ansari, S. H., Lassi, Z. S., Khowaja, S. M., Adil, S. O. & Shamsi, T. S. Hydroxyurea (hydroxycarbamide) for transfusion\u2010dependent \u03b2\u2010thalassaemia. Cochrane Database System. Rev. (2019).","DOI":"10.1002\/14651858.CD012064.pub2"},{"key":"6774_CR21","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1182\/blood-2015-03-633594","volume":"125","author":"S Mettananda","year":"2015","unstructured":"Mettananda, S., Gibbons, R. J. & Higgs, D. R. alpha-Globin as a molecular target in the treatment of beta-thalassemia. Blood 125, 3694\u20133701 (2015).","journal-title":"Blood"},{"key":"6774_CR22","doi-asserted-by":"publisher","first-page":"e0220852","DOI":"10.1371\/journal.pone.0220852","volume":"14","author":"AP Premawardhana","year":"2019","unstructured":"Premawardhana, A. P. et al. A nationwide survey of hospital-based thalassemia patients and standards of care and a preliminary assessment of the national prevention program in Sri Lanka. PLoS ONE 14, e0220852 (2019).","journal-title":"PLoS ONE"},{"key":"6774_CR23","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.3324\/haematol.2016.155655","volume":"102","author":"S Mettananda","year":"2017","unstructured":"Mettananda, S. et al. Selective silencing of alpha-globin by the histone demethylase inhibitor IOX1: A potentially new pathway for treatment of beta-thalassemia. Haematologica 102, e80\u2013e84 (2017).","journal-title":"Haematologica"},{"key":"6774_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nature15521","volume":"527","author":"MC Canver","year":"2015","unstructured":"Canver, M. C. et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 527, 192\u2013197 (2015).","journal-title":"Nature"},{"key":"6774_CR25","doi-asserted-by":"publisher","first-page":"11649","DOI":"10.1038\/s41598-019-48204-2","volume":"9","author":"S Mettananda","year":"2019","unstructured":"Mettananda, S. et al. Synergistic silencing of alpha-globin and induction of gamma-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for beta-thalassaemia. Sci. Rep. 9, 11649 (2019).","journal-title":"Sci. Rep."},{"key":"6774_CR26","doi-asserted-by":"publisher","first-page":"752278","DOI":"10.3389\/fgeed.2021.752278","volume":"3","author":"S Mettananda","year":"2021","unstructured":"Mettananda, S. Genetic and epigenetic therapies for \u03b2-thalassaemia by altering the expression of \u03b1-globin gene. Front Genome Ed. 3, 752278 (2021).","journal-title":"Front Genome Ed."},{"key":"6774_CR27","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1182\/blood-2003-01-0117","volume":"102","author":"M Bradai","year":"2003","unstructured":"Bradai, M. et al. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood 102, 1529\u20131530 (2003).","journal-title":"Blood"},{"key":"6774_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0140-6736(11)60283-3","volume":"379","author":"DR Higgs","year":"2012","unstructured":"Higgs, D. R., Engel, J. D. & Stamatoyannopoulos, G. Thalassaemia. Lancet 379, 373\u2013383 (2012).","journal-title":"Lancet"},{"key":"6774_CR29","doi-asserted-by":"publisher","first-page":"100588","DOI":"10.1016\/j.blre.2019.100588","volume":"37","author":"FT Shah","year":"2019","unstructured":"Shah, F. T., Sayani, F., Trompeter, S., Drasar, E. & Piga, A. Challenges of blood transfusions in \u03b2-thalassemia. Blood Rev. 37, 100588 (2019).","journal-title":"Blood Rev."},{"key":"6774_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/bjh.16687","volume":"189","author":"NBA Roy","year":"2020","unstructured":"Roy, N. B. A. et al. Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic. Br. J. Haematol. 189, 635\u2013639 (2020).","journal-title":"Br. J. Haematol."},{"key":"6774_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12887-020-02160-3","volume":"20","author":"H Reed-Embleton","year":"2020","unstructured":"Reed-Embleton, H. et al. A cost-of-illness analysis of \u03b2-Thalassaemia major in children in Sri Lanka: Experience from a tertiary level teaching hospital. BMC Pediatr. 20, 257 (2020).","journal-title":"BMC Pediatr."},{"key":"6774_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.hoc.2017.11.003","volume":"32","author":"S Mettananda","year":"2018","unstructured":"Mettananda, S. & Higgs, D. R. Molecular basis and genetic modifiers of thalassemia. Hematol. Oncol. Clin. North Am. 32, 177\u2013191 (2018).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"6774_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/nyas.12988","volume":"1368","author":"S Mettananda","year":"2016","unstructured":"Mettananda, S., Gibbons, R. J. & Higgs, D. R. Understanding alpha-globin gene regulation and implications for the treatment of beta-thalassemia. Ann. N. Y. Acad. Sci. 1368, 16\u201324 (2016).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"6774_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.freeradbiomed.2021.02.028","volume":"166","author":"A Allen","year":"2021","unstructured":"Allen, A. et al. Oxidative status in the \u03b2-thalassemia syndromes in Sri Lanka; a cross-sectional survey. Free Radic. Biol. Med. 166, 337\u2013347 (2021).","journal-title":"Free Radic. Biol. Med."},{"key":"6774_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4038\/sljch.v47i2.8484","volume":"47","author":"S Mettananda","year":"2018","unstructured":"Mettananda, S. Management of Thalassaemia. Sri Lanka J. Child Health 47, 159\u2013165 (2018).","journal-title":"Sri Lanka J. Child Health"},{"key":"6774_CR36","doi-asserted-by":"publisher","first-page":"e041958","DOI":"10.1136\/bmjopen-2020-041958","volume":"10","author":"N Yasara","year":"2020","unstructured":"Yasara, N. et al. Protocol: Efficacy and safety of oral hydroxyurea in transfusion-dependent \u03b2-thalassaemia: A protocol for randomised double-blind controlled clinical trial. BMJ Open 10, e041958 (2020).","journal-title":"BMJ Open"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06774-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06774-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06774-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:01:14Z","timestamp":1669312874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06774-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6774"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-06774-8","relation":{"has-review":[{"id-type":"doi","id":"10.32388\/TSDQG0","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"30 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2752"}}